Race's first important asset is a chemotherapy drug called Bisantrene which was the subject of more than 40 phase II clinical studies before it was lost in a series of pharmaceutical mergers during the 1990s. Race Oncology has rediscovered Bisantrene and we plan to put this valuable drug back in the hands of clinicians to treat Leukaemia.
We own recent patent filings on Bisantrene and have secured Orphan Drug Designation in the US. We now aim to bring this valuable drug to market.
Race Oncology CEO Peter Molloy and Chair Dr Bill Garner.
Race Oncology is pleased to announce the company has been invited to present at the ‘Biotech
Swiss biotech company TargImmune is announcing a new international research collaboration with
In November 2017, Race CEO Peter Molloy spoke to investors in London at the Biotech & Money
What is Bisantrene and where did it come from? Click here to watch CEO Peter Molloy’s
A Perth family tells the story of their son’s battle with Acute Myeloid Leukaemia. When Kai got
Race Oncology Limited (RAC) is pleased to announce it has produced its first good manufacturing